Researcher

Aubrey de Grey

Last updated Mon Jun 08 2026 00:00:00 GMT+0000 (Coordinated Universal Time)· 2 min read

Background

Aubrey de Grey trained in computer science at Cambridge, then self-trained in biogerontology while working as a researcher in his wife’s Cambridge biology lab. He published Ending Aging (with Michael Rae) in 2007 and founded the SENS Research Foundation in 2009. After departing SENS in 2021 amid organisational controversy, he founded the LEV Foundation, which pursues a similar but distinct mouse-lifespan- focused research programme.

The SENS framework

SENS (Strategies for Engineered Negligible Senescence) organises age-related damage into seven categories and proposes a repair strategy for each:

Cell loss / atrophy — stem-cell and growth-factor therapies.
Cell senescence — selective ablation (senolytics).
Nuclear mutations / epimutations — primarily cancer-targeting therapies (the WILT proposal — very controversial).
Mitochondrial mutations — allotopic expression of the 13 mtDNA-encoded proteins from the nucleus.
Intracellular junk (lipofuscin, aggregates) — lysosomal augmentation with novel hydrolases for indigestible material.
Extracellular junk (amyloids, AGEs, oxidised cholesterol) — immunotherapy and cyclodextrin-based clearance approaches.
Extracellular crosslinks — small molecules to break advanced glycation end-product crosslinks.

The framework’s strength is that it converts “aging is hard” into a specific, tractable engineering punch-list. The weakness is that sub-projects vary enormously in tractability and several (WILT, full allotopic mtDNA expression) remain extremely distant from clinical translation.

Companies and projects rooted in SENS

Substantial parts of the modern longevity-biotech industry trace to SENS-funded foundational work:

Cyclarity (formerly Underdog Pharmaceuticals) — 7-ketocholesterol cyclodextrin-based atherosclerosis clearance.
Early senolytic work (multiple academic programmes).
Glucosepane cross-link breaker projects.
Allotopic expression research (still pre-clinical).

LEV Foundation

Since 2022, the Longevity Escape Velocity Foundation has pursued a parallel research agenda focused on combination interventions in mouse lifespan studies. The bet: that combining several mid-strength interventions (rapamycin, senolytics, telomerase gene therapy, others) produces super-additive effects worth showing in mouse cohorts.

Reception

A polarising figure

de Grey’s "damage repair" framing has become substantially more mainstream than when introduced — specific sub-projects have produced peer-reviewed advances and biotech companies. His public timelines ("longevity escape velocity in 17 years" and similar statements) are not shared by most working geroscientists. He himself remains a personally controversial figure following events at SENS in 2021. Read his scientific arguments on their own merits; weigh his timelines against the broader field’s assessment.

References

de Grey, A. D. N. J. & Rae, M. Ending Aging. St. Martin's Press (2007).
de Grey, A. D. N. J. A roadmap to end aging. TED talk (2005).